Home » Stocks » PRFX

PainReform Ltd. (PRFX)

Stock Price: $4.63 USD 0.06 (1.31%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $4.54 -0.09 (-1.94%) Nov 27, 3:34 PM

Stock Price Chart

Key Info

Market Cap 41.25M
Revenue (ttm) n/a
Net Income (ttm) -1.28M
Shares Out 8.75M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $4.63
Previous Close $4.57
Change ($) 0.06
Change (%) 1.31%
Day's Open 4.61
Day's Range 4.51 - 4.66
Day's Volume 39,843
52-Week Range 4.03 - 7.85

More Stats

Market Cap 41.25M
Enterprise Value 47.50M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 8.75M
Float 3.23M
EPS (basic) n/a
EPS (diluted) -0.15
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3,028
Short Ratio 0.02
Short % of Float 0.09%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -1.28M
Free Cash Flow n/a
Net Cash -6.24M
Net Cash / Share -0.70
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -95.49%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $4.63
Target: 10.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-0.69-0.50
Net Income-1.28-0.83
Shares Outstanding0.580.58
Earnings Per Share-4.17-3.24
Operating Cash Flow-0.61-0.64
Free Cash Flow-0.61-0.64
Cash & Equivalents0.950.05
Total Debt6.174.52
Net Cash / Debt-5.23-4.47
Book Value-12.24-11.08
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PainReform Ltd.
Country Israel
Employees 3
CEO Eli Hazum

Stock Information

Ticker Symbol PRFX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: PRFX
IPO Date September 1, 2020


PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Our proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. Our strategy is to incorporate generic drugs with our proprietary extended release drug-delivery system in order to create extended release drug products and to take advantage of the 505(b)(2) regulatory pathway created by the U.S. Food and Drug Administration (“FDA”). The 505(b)(2) new drug application (“NDA”) process, provides for FDA approval of a new drug based in part on data that was developed by others, including published literature references and data previously reviewed by the FDA in its approval of a separate application. Using this pathway can significantly reduce the future time and costs associated with clinical development. PRF-110, our first product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia.